这一通路的另一个抑制性受体PVRIG（Poliovirus receptor-related Ig domain containing protein）于2016年被报道，它由科罗拉多大学Yuwen Zhu课题组与以色列Compugen公司通过大规模的生物信息学分析分别独立发现，为TIGIT/CD226通路又增添了一层复杂性。 PVRIG与CD155和CD112等同属PVR家族，其胞外区具有一个IgV结构域，胞内区较长，含一个ITIM结构域。 PVRIG的mRNA主要存在于T细胞和NK细胞上，而在T细胞激活后会表达会进一步增高； 抗体 …

2021年12月1日 · This study explored the novel immune checkpoint poliovirus receptor-related immunoglobulin domain-containing (PVRIG) in acute myeloid leukemia (AML). We showed that AML patient blasts consistently expressed the PVRIG ligand (poliovirus receptor-related 2, PVRL2). Furthermore, PVRIG blockade signific …

2022年12月7日 · pvrig是一种新型b7/cd28样免疫检查点蛋白 ，pvrl2是pvrig的配体。临床前实验结果显示，在对靶向pd-1免疫疗法耐药的患者中，癌细胞中较高的pvrl2水平 ...

2024年7月2日 · Using spatial and single-cell RNA transcriptomics data across diverse cancer indications, we found that among the T-cell checkpoints, PVRIG is uniquely expressed on TSCM and PVRL2 is expressed on DCs in immune aggregate niches in tumors. PVRIG blockade could therefore enhance TSCM-DC interactions and efficiently drive T-cell infiltration to tumors.

2025年2月8日 · PVRIG is a novel NK cell immune checkpoint receptor in acute myeloid leukemia. we demonstrate that PVRIG and PVRL2 are expressed in human cancers and the PVRIG-PVRL2 and TIGIT-PVR pathways are nonredundant inhibitory signaling pathways.

PVRIG is a recently identified immune checkpoint receptor and blockade of which could reverse T cell exhaustion to treat murine tumor; however, its therapeutic potential via NK cells in mice and human remains seldom reported.

在肿瘤微环境中，tigit与配体cd155 结合，pvrig与配体cd112 结合，会抑制t 细胞的增殖和活化，抑制nk细胞的杀伤作用，并导致肿瘤细胞的免疫逃逸。因此，联合阻断tigit 和pvrig 可显著提高抗肿瘤效果 [2] 。 tigit/pvrig在肿瘤中的作用机制

2021年6月26日 · PVRIG is a recently identified immune checkpoint receptor and blockade of which could reverse T cell exhaustion to treat murine tumor; however, its therapeutic potential via NK cells in mice and human remains seldom reported.

PVRIG (CD112R) is an inhibitory immune-checkpoint receptor that binds only to its ligand CD112 (Nectin-2) with high affinity on target cells suppressing lymphocyte cytotoxic function. CD112R is expressed in CD4+ and CD8+T cells, γδ T, NKT, and NK cells. CD112R interacts with CD112 competing with DNAM-1 but not with CD155 (PVR).

2025年3月1日 · Our data highlight the unique dominant PVRIG expression among patients with relapsed/refractory MM and suggests new potential therapeutic strategy of blocking PVRIG in combination with T-cell engagers.